title: Experience from the Argentine Pegvisomant Observational Study: preliminary data.
abstract: The GH receptor antagonist pegvisomant is an efficient agent to achieve biochemical control of acromegaly in those cases refractory to surgery and medical therapy with somatostatin analogs. We conducted an observational multicenter study consisting of data collection in accordance with the standard management of patients with acromegaly in everyday practice. We reviewed the medical records of 28 patients, 23 females, who were treated with pegvisomant due to the lack of biochemical response or intolerance to the somatostatin analogs. The objective was to monitor long-term safety and efficacy of the antagonist. 82% of the patients had previous pituitary surgery, 53.6% radiotherapy and 96.4% received medical therapy for acromegaly. Only 19.2% of the patients had pituitary residual tumor size larger than 1 cm, the remainder harbored a microadenoma or no visible tumor in the pituitary images. In terms of biochemical efficacy, IGF-I levels decreased to normal ranges in 45% and 58.8% of patients after 3 and 6 months of treatment, respectively, the daily mean dose of pegvisomant being 9.6+/-1.1 mg. Adverse events, potentially related to pegvisomant were reported in 6 patients (21.4%), local injection site reaction and elevated liver enzymes being the most frequent. Tumor size did not show enlargement in the evaluated population (15 patients) during the period of the study. This paper presents preliminary data from a small observational study in Argentina which represents the first database in our country.
authors.forename: N
authors.initials: N
authors.lastname: García Basavilbaso
authors.forename: M
authors.initials: M
authors.lastname: Guitelman
authors.forename: A
authors.initials: A
authors.lastname: Nagelberg
authors.forename: G
authors.initials: G
authors.lastname: Stalldecker
authors.forename: A
authors.initials: A
authors.lastname: Carabelli
authors.forename: O
authors.initials: O
authors.lastname: Bruno
authors.forename: K
authors.initials: K
authors.lastname: Danilowitz
authors.forename: M
authors.initials: M
authors.lastname: Manavela
authors.forename: S
authors.initials: S
authors.lastname: Mallea Gil
authors.forename: C
authors.initials: C
authors.lastname: Ballarino
authors.forename: R
authors.initials: R
authors.lastname: Guelman
authors.forename: D
authors.initials: D
authors.lastname: Katz
authors.forename: S
authors.initials: S
authors.lastname: Fidalgo
authors.forename: R
authors.initials: R
authors.lastname: Leal
authors.forename: H
authors.initials: H
authors.lastname: Fideleff
authors.forename: M
authors.initials: M
authors.lastname: Servidio
authors.forename: D
authors.initials: D
authors.lastname: Bruera
authors.forename: F
authors.initials: F
authors.lastname: Librandi
authors.forename: A
authors.initials: A
authors.lastname: Chervin
authors.forename: M
authors.initials: M
authors.lastname: Vitale
authors.forename: A
authors.initials: A
authors.lastname: Basso
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D005260:Female; D019382:Human Growth Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors*
chemical_list: D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; C406545:pegvisomant